Sepsis Therapeutics Market Size, Share & Trends Analysis and Forecast 2021 – 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The global sepsis market has been valued at $3.48 billion in 2020 and is expected to grow at a CAGR of more than 7.5% across the seven major pharmaceutical markets (7MM) the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan during the forecast period. As of 2020, the market has been dominated by antibiotics and supportive therapies for the treatment of sepsis, most of which are available as generic versions. Due to its high diagnosed incidence rate of sepsis, the US market constitutes more than 69% of the 7MM sepsis market in 2020.
The growth in the sepsis market is being driven by the projected increase in sepsis and the launch of new therapies. While the 7MM population is expected to increase by more than 2% during the forecast period, the number of sepsis and septic shock incident cases is also expected to increase. This market growth is expected to be due to improved sepsis diagnostic abilities, and by the anticipated launch of new sepsis therapeutics with novel mechanisms of action (MOAs), such as monoclonal antibodies, recombinant proteins, and synthetic peptides, during the forecast period. Current clinical trials of these new agents suggest that they will supplement existing antibiotic therapies while replacing existing supportive therapies.
Overview of the Sepsis market
For more insights on this report, download a free report sample
What are the market dynamics and market barriers for the Sepsis market?
The major drivers of the growth within the sepsis market includes the launch of four new pipeline drugs: adrecizumab, Motrem, recap, and CYT107, and an increased prevalence of sepsis and septic shock across the 7MM that together with improved awareness of sepsis, will result in a larger treated patient population.
Also, with this, the major barriers to the growth of the market include, the high cost of the biologics that are likely to represent a major barrier for physicians prescribing these medications, the complexity inherent to multiple organ involvement in sepsis and septic shock continues to hinder the development of safe and tolerable agents that are effective at treating all manifestations of sepsis, the randomized controlled trials (RCTs) will assist in reducing the heterogeneity observed in these trials, and the impact of the COVID-19 pandemic has thus resulted in serious delays of clinical trials for the sepsis pipeline therapeutics.
What is the country-based Sepsis market trends?
In the 7MM, the US had the highest diagnosed incidence of sepsis in 2020, and the UK had the lowest diagnosed incidence in 2020. The rate of increase was found to be highest in the US, rising from 306.81 cases per 100,000 population in 2010 to 492.47 cases per 100,000 population in 2020. The UK had the lowest rate of increase in incidence from 2010–2020. This increase is driven by the growing aging population and the rising incidence of comorbidities in the affected population.
In the 7MM, the US had the highest diagnosed incidence of septic shock in 2020 (99.46 cases per 100,000 population), and the UK had the lowest diagnosed incidence in 2020 (19.51 cases per 100,000 population). The rate of increase was highest in the US, rising from 63.47 cases per 100,000 population in 2010 to 99.46 cases per 100,000 population in 2020. The UK had the lowest rate of increase in incidence from 2010–2020.
Diagnosed incidence of Sepsis, cases per 100,000 population
For more insights, download a free report sample
How has the global COVID-19 pandemic impacted the Sepsis market?
The COVID-19 pandemic has directly impacted several clinical trials in the sepsis therapy area. However, many companies in the sepsis therapeutic area have a unique position in the pharmaceutical market, as they can benefit from the COVID-19 situation. Many pipelines and marketed sepsis drugs are currently enrolled in various clinical trials to treat COVID-19. Inotrem announced in July 2021 that it has obtained authorization to pursue the clinical development of Motrem in COVID-19 patients from both the French and Belgian competent authorities.
AM-Pharma was also engaged in Phase III clinical trial testing recAP on COVID-19 patients with SA-AKI. It is unknown whether the COVID-19 clinical trials will have an impact on the duration and/or success of the sepsis trials, such as if the COVID-19 trials are prioritized or receive extra resources at the expense of clinical trials for patients with sepsis.
What are the disease management and treatment overview for Sepsis?
Antibiotics are found to be the mainstay of treatment for sepsis because most causative infections result from bacterial colonization. Antibiotics have been shown to significantly decrease mortality when they are given within an hour of diagnosis of sepsis, compared to after an hour.
If sepsis is caused by a virus, fungus, or parasite, then the use of antivirals, antifungals, and antiparasitic, respectively, will become a critical component of disease management for the affected patient. The other treatments include fluid therapies, vasopressor, anticoagulant, immunomodulator and medical devices.
What are the key players in the Sepsis market?
As of August 2021, there were more than 270 companies developing drug candidates for the treatment of sepsis in the 7MM. Some of the major players involved are Adrenomed A.G., AM-Pharma B.V., Asahi Kasei Pharma, Grifols, Inotrem, La Jolla, Merck, Pfizer, Sanofi and RevImmune.
Sepsis market, by key players
For more insights, download a free report sample
Market report scope
Market size of profit sector
(Year – 2020) |
$3.48 billion |
Growth rate of profit sector | CAGR of >7.5% from 2021 to 2025 |
Base year for estimation | 2020 |
Market segments by country | The US, France, Germany, Italy, Spain, the UK, and Japan |
Forecast period | 2021–2025 |
Key players | Adrenomed A.G., AM-Pharma B.V., Asahi Kasei Pharma, Grifols, Inotrem, La Jolla, Merck, Pfizer, Sanofi and RevImmune. |
Scope
This report provides a comprehensive analysis of the Sepsis market-
- Overview of sepsis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline sepsis therapeutics market revenue from 2020–2030. The annual cost of therapy and major pipeline product sales in this forecast period are included.
- Key topics covered include current sepsis therapies, unmet needs and opportunities, and the drivers and barriers affecting treatment sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global sepsis therapeutic market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global sepsis therapeutic market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the sepsis therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table
Figures
Frequently asked questions
-
What is the value of the Sepsis market in 2020?
The Sepsis market was valued at $3.48 billion in 2020.
-
What is the growth rate of the Sepsis market?
The Sepsis market is projected to grow at a CAGR of more than 7.5% during the forecast period 2021-2025.
-
What are the key countries in the Sepsis market?
There are seven major pharmaceutical markets (7MM) covered in this report: The US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan.
-
Who are the major players in the Sepsis market?
Some of the major players involved are Adrenomed A.G., AM-Pharma B.V., Asahi Kasei Pharma, Grifols, Inotrem, La Jolla, Merck, Pfizer, Sanofi, and RevImmune.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.